WO1997021678A1 - Carbamic acid derivatives as leukotriene antagonists - Google Patents
Carbamic acid derivatives as leukotriene antagonists Download PDFInfo
- Publication number
- WO1997021678A1 WO1997021678A1 PCT/EP1996/005248 EP9605248W WO9721678A1 WO 1997021678 A1 WO1997021678 A1 WO 1997021678A1 EP 9605248 W EP9605248 W EP 9605248W WO 9721678 A1 WO9721678 A1 WO 9721678A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- formula
- carbon atoms
- straight
- chain
- Prior art date
Links
- 150000004657 carbamic acid derivatives Chemical class 0.000 title claims abstract description 15
- 239000003199 leukotriene receptor blocking agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 10
- 150000002617 leukotrienes Chemical class 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 239000003112 inhibitor Substances 0.000 claims abstract description 5
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 5
- -1 dicyclohexylmethyl Chemical group 0.000 claims description 43
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims description 6
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000004305 biphenyl Substances 0.000 claims description 6
- 235000010290 biphenyl Nutrition 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical group 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 229940083608 sodium hydroxide Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KIUPCUCGVCGPPA-UHFFFAOYSA-N (5-methyl-2-propan-2-ylcyclohexyl) carbonochloridate Chemical compound CC(C)C1CCC(C)CC1OC(Cl)=O KIUPCUCGVCGPPA-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- MIGYSVUMANZSLB-UHFFFAOYSA-N lithium;butylazanide Chemical compound [Li+].CCCC[NH-] MIGYSVUMANZSLB-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- ZGSXCGTUPZOUPE-UHFFFAOYSA-N oxolane;tetrachloromethane Chemical compound C1CCOC1.ClC(Cl)(Cl)Cl ZGSXCGTUPZOUPE-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical class [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Definitions
- the invention relates to carbamic acid derivatives, process for their preparation and their use in medicaments
- Leukotrienes are arachidonic acid metabolites produced by the 5-l ⁇ poxygenase pathway in activated phagocytes and are important mediators of bronchial asthma and acute inflammation The pathophysiological importance of leukotrienes suggests that selective inhibitors of leukotriene synthesis may be useful anti- allergic and anti-inflammatory therapeutic agents
- the invention relates to carbamic acid derivatives of the general formula (I)
- R 1 represents a 6 membered aromatic heterocycle having up to 2 nitrogen atoms and to which a phenyl ring can be fused and wherein the rings optionally are monosubstituted or disubstituted by identical or different substituents from the series comprising halogen, carboxyl, nitro or a straight-chain or branched alkoxycarbonyl having up to 6 carbon atoms or by a group of the formula -(CO) -NRY 4
- a denotes a number 0 or 1 ,
- R 1 and R 4 are identical or different and denote hydrogen, biphenyl, phenyl, adamantyl or straight-chain or branched alkyl oi ac ⁇ l each having up to 6 carbon atoms, which optionally are monosubstituted or disubstituted by phenyl and/or hydroxyl,
- R ⁇ represents adamantyl, cycloalkyl having 3 to 6 carbon atoms, pyridyl, phenyl or benzyl, which optionally are substituted by halogen, carboxyl or straight-chain or branched alkoxy or alkoxycarbonyl each having up to 6 carbon atoms, or represents a group of the formula
- A represents adamantyl, dicyclohexylmethyl, cyclododecyl, cis-decahydro-1 - naphthyl, 4-tert.butylphenyl, 2-naphthyl, 2,6-diphenylphenyl, dibenzo- suberolyl, 2-methylbenzyl, ⁇ -cyclopropyl-benzyl, 9-hydroxy-phenanthrenyl, 4-tritylphenyl, or represents a residue of the formula and then salts
- the compound of the general formula (I) can also be present in the form of their salts in general, salts with organic or inorganic bases or acids may be mentioned here
- Physiologically acceptable salts are preferred Physiologically acceptable salts of the carbamic acid derivatives can be metal or ammonium salts of the substances according to the invention, which contain a free carboxylic group Those which are particularly preferred are, for example, sodium, potassium, magnesium or cal ⁇ cium salts, and also ammonium salts which are derived from ammonia, or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanol ⁇ amine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylene ⁇ diamine
- Physiologically acceptable salts can also be salts of the compounds according to the invention with inorganic or organic acids
- Preferred salts here are those with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid, or salts with organic carboxylic or sulphonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, ethanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid
- the compounds according to the invention can exist in stereoisome ⁇ c forms which either behave as image and mirror image (enantiomers), or which do not behave as image and mirror image (diastereomers)
- the invention relates both to the anti ⁇ podes and to the racemate forms, as well as the mixture of diastereomers
- the racemate forms, like the diastereomers, can be separated into the stereoisome ⁇ - cally uniform constituents in a known manner
- Preferred compounds of the general formula (I) are those
- R 1 represents isoquinolyl, pyrazinyl, pyridyl or pyrimidyl, which optionally are monosubstituted or disubstituted by identical or different substituents from the series comprising fluorine, chlorine, bromine, iodine, carboxyl, nitro or a straight-chain or branched alkoxycarbonyl having up to 5 carbon atoms or by a group of the formula -(CO) a -NR 3 R 4 ,
- a denotes a number 0 or 1
- R 3 and R 4 are identical or different and denote hydrogen, biphenyl, phenyl, adamantyl or straight-chain or branched alkyl or acyl each having up to 5 carbon atoms, which optionally are monosubstituted or di ⁇ substituted by phenyl and/or hydroxyl,
- R 2 represents cyclopentyl, cyclohexyl, pyridyl, phenyl or benzyl, which optionally are substituted by fluorine, chlorine, bromine, carboxyl, straight- chain or branched alkoxy or alkoxycarbonyl each having up to 4 carbon atoms, or represents the group of the formula
- R 1 and R 2 including the nitrogen atom together form a residue of a formula
- A represents adamantyl, dicyclohexylmethyl, cyclododecanyl, cis-decahydro-
- Particularly preferred compounds are those of the general formula (I),
- R represents pyridyl or pyrimidyl, which optionally are monosubstituted or disubstituted by identical or different substituents from the series comprising fluorine, chlorine, bromine, carboxyl, nitro or a straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms or by a group of the formula -(CO) r NR 3 R 4 ,
- R denotes a number 0 or R s and R are identical or different and denote hydrogen, biphenyl, phenyl, adamantyl, straight-chain or branched alkyl or acyl each having up to 3 carbon atoms, which are optionally monosubstituted or disub ⁇ stituted by phenyl and/or hydroxyl,
- R 2 represents cyclopentyl, cyclohexyl, pyridyl or phenyl, which optionally are substituted by fluorine, chlorine, bromine, carboxyl, straight-chain or branched alkoxy or alkoxycarbonyl each having up to 3 carbon atoms, or represents the group of the formula
- T represents halogen, preferably chlorine
- Suitable solvents are generally customary organic solvents which do not change under the reaction conditions
- T hese include ethers such as diethyl ether, dioxane or tetrahydrofuran, acetone, dimethylsulfoxide, dimethylformamide or alcohols such as methanol, ethanol, propanol or halogenohydrocarbons such as dichlor- methane, t ⁇ chloromethane or tetrachloromethane Tetrahydrofuran is preferred
- Suitable bases are generally inorganic or organic bases These preferably include alkali metal hydroxides such as, for example, sodium hydroxide, sodium hydrogen- carbonate or potassium hydroxide, alkaline earth metal hydroxides such as, for example, barium hydroxide, alkali metal carbonates such as sodium carbonate, potassium carbonate, alkaline earth metal carbonates such as calcium carbonate, or alkaline metal or organic amines (trialkyl(C ] -C 6 )amines) such as triethylamine, or heterocycles such as l,4-d ⁇ azab ⁇ cyclo[2 2 2]octane (DABCO), 1,8-d ⁇ azab ⁇ cyclo- [5 4 0]undec-7-ene (DBU), or amides such as sodium amides, lithium butyl amide or butyllithium, pyridine or methylpipe ⁇ dine It is also possible to employ alkali metals, such as sodium or its hydrides such as sodium hydride, as bases
- the process is in general carried out in a temperature range from 0°C to +100°C, preferably from room temperature to +60°C
- the process is generally carried out at normal pressure However, it is also possible to carry out it at elevated pressure or at reduced pressure (for example in a range from 0 5 to 5 bar)
- the base is employed in an amount from 1 mol to 10 mol, preferably from 1 0 mol to 4 mol, relative to 1 mol of the compounds of the general formula (III)
- the compounds of the general formula (III) are known or can be prepared by customary methods
- the carbamic acid derivatives of the general formula (I) can be employed as active compounds in medicaments.
- the substances can act as inhibitors of enzy ⁇ matic reactions in the context of arachidonic acid metabolism.
- the compounds of the general formula (I) surprisingly show a high activity as inhibitors of leukotriene synthesis, specifically inhabit the production of leuko ⁇ triene B 4 in polymorphonuclear leucocytes (PMNL).
- the new active compounds can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, nontoxic, pharmaceuti- cally suitable excipients or solvents
- the therapeutically active compound should in each case be present in a concentration of about 0 5 to 90% by weight of the total mixture, l e in amounts which are sufficient in order to achieve the dosage range indicated
- the formulations are prepared, for example, by extending the active compounds with solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, where, for example, in the case of the use of water as a diluent, organic solvents can be used as auxiliary solvents if appropriate
- Administration is carried out in a customary manner, preferably orally or paren ⁇ terally, in particular perhngually or intravenously
- solutions of the active compound can be employed using suitable liquid vehicles
- intravenous administration amounts from about 10 to 100 mg/kg, preferably about 10 to 50 mg/kg of body weight to achieve effective results, and on oral administration the dosage is about 10 to 100 mg/kg, preferably 10 to 50 mg/kg of body weight
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Carbamic acid derivatives are prepared by reacting amines with appropriately substituted halo-formates. The compounds act as inhibitors of the leukotrienes synthesis and therefore can be used as active ingredients in medicaments.
Description
CARBAMIC ACID DERIVATIVES AS LEUKOTRIENE ANTAGONISTS
The invention relates to carbamic acid derivatives, process for their preparation and their use in medicaments
Leukotrienes are arachidonic acid metabolites produced by the 5-lιpoxygenase pathway in activated phagocytes and are important mediators of bronchial asthma and acute inflammation The pathophysiological importance of leukotrienes suggests that selective inhibitors of leukotriene synthesis may be useful anti- allergic and anti-inflammatory therapeutic agents
Carbamic acid, phenyI-2-pyπdιnyl-4-phenyl and benzyl esters are described as 5- poxygenase and cyclooxygenase inhibitors or antitumor medicaments in the publications EP 472 053 A2, EP 347 698 Al, J Pharm, Sci (1976), 65 (10), 1505- 10, J Prakt Chem 328, (1986), 3, 393-400
The invention relates to carbamic acid derivatives of the general formula (I)
R1
, N W
R C02-A v -
in which
R1 represents a 6 membered aromatic heterocycle having up to 2 nitrogen atoms and to which a phenyl ring can be fused and wherein the rings optionally are monosubstituted or disubstituted by identical or different substituents from the series comprising halogen, carboxyl, nitro or a straight-chain or branched alkoxycarbonyl having up to 6 carbon atoms or by a group of the formula -(CO) -NRY4
in which
a denotes a number 0 or 1 ,
R1 and R4 are identical or different and denote hydrogen, biphenyl, phenyl, adamantyl or straight-chain or branched alkyl oi ac\ l each having
up to 6 carbon atoms, which optionally are monosubstituted or disubstituted by phenyl and/or hydroxyl,
. 1
R~ represents adamantyl, cycloalkyl having 3 to 6 carbon atoms, pyridyl, phenyl or benzyl, which optionally are substituted by halogen, carboxyl or straight-chain or branched alkoxy or alkoxycarbonyl each having up to 6 carbon atoms, or represents a group of the formula
or
R1 and R2 including the nitrogen atom together form a residue of the formula
A represents adamantyl, dicyclohexylmethyl, cyclododecyl, cis-decahydro-1 - naphthyl, 4-tert.butylphenyl, 2-naphthyl, 2,6-diphenylphenyl, dibenzo- suberolyl, 2-methylbenzyl, α-cyclopropyl-benzyl, 9-hydroxy-phenanthrenyl, 4-tritylphenyl, or represents a residue of the formula
and then salts
The compound of the general formula (I) can also be present in the form of their salts in general, salts with organic or inorganic bases or acids may be mentioned here
Physiologically acceptable salts are preferred Physiologically acceptable salts of the carbamic acid derivatives can be metal or ammonium salts of the substances according to the invention, which contain a free carboxylic group Those which are particularly preferred are, for example, sodium, potassium, magnesium or cal¬ cium salts, and also ammonium salts which are derived from ammonia, or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanol¬ amine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylene¬ diamine
Physiologically acceptable salts can also be salts of the compounds according to the invention with inorganic or organic acids Preferred salts here are those with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid, or salts with organic carboxylic or sulphonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, ethanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid
The compounds according to the invention can exist in stereoisomeπc forms which either behave as image and mirror image (enantiomers), or which do not behave as image and mirror image (diastereomers) The invention relates both to the anti¬ podes and to the racemate forms, as well as the mixture of diastereomers The racemate forms, like the diastereomers, can be separated into the stereoisomeπ- cally uniform constituents in a known manner
Preferred compounds of the general formula (I) are those
in which
R1 represents isoquinolyl, pyrazinyl, pyridyl or pyrimidyl, which optionally are monosubstituted or disubstituted by identical or different substituents from the series comprising fluorine, chlorine, bromine, iodine, carboxyl, nitro or a straight-chain or branched alkoxycarbonyl having up to 5 carbon atoms or by a group of the formula -(CO)a-NR3R4,
in which
a denotes a number 0 or 1,
R3 and R4 are identical or different and denote hydrogen, biphenyl, phenyl, adamantyl or straight-chain or branched alkyl or acyl each having up to 5 carbon atoms, which optionally are monosubstituted or di¬ substituted by phenyl and/or hydroxyl,
R2 represents cyclopentyl, cyclohexyl, pyridyl, phenyl or benzyl, which optionally are substituted by fluorine, chlorine, bromine, carboxyl, straight- chain or branched alkoxy or alkoxycarbonyl each having up to 4 carbon atoms, or represents the group of the formula
or
R1 and R2 including the nitrogen atom together form a residue of a formula
A represents adamantyl, dicyclohexylmethyl, cyclododecanyl, cis-decahydro-
1-naphthyl, 4-tert butylphenyl, 2-naphthyl, 2,6-dιphenylphenyl, dibenzo- suberolyl, 2-methylbenzyl, α-cyclopropyl-benzyl, 9-hydroxy-phenanthrenyl, 4-tπtylphenyl, or represents a residue of the formula
Particularly preferred compounds are those of the general formula (I),
in which
R represents pyridyl or pyrimidyl, which optionally are monosubstituted or disubstituted by identical or different substituents from the series comprising fluorine, chlorine, bromine, carboxyl, nitro or a straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms or by a group of the formula -(CO) rNR3R4,
in which
denotes a number 0 or
Rs and R are identical or different and denote hydrogen, biphenyl, phenyl, adamantyl, straight-chain or branched alkyl or acyl each having up to 3 carbon atoms, which are optionally monosubstituted or disub¬ stituted by phenyl and/or hydroxyl,
R2 represents cyclopentyl, cyclohexyl, pyridyl or phenyl, which optionally are substituted by fluorine, chlorine, bromine, carboxyl, straight-chain or branched alkoxy or alkoxycarbonyl each having up to 3 carbon atoms, or represents the group of the formula
represents adamantyl, dtcyclohexylmethyl, cyclododecanyl, cis-decahydro-
1-naphthyl, 4-tert butylphenyl, 2-naphthyl, 2,6-diphenylphenyl, dibenzo- suberolyl, 2-methylbenzyl, -cyclopropyl-benzyl, 9-hydroxy-phenanthrenyl,
4-tπtylphenyl, or a residue of the formula
and their salts
Additionally a process for the preparation of the compounds of the general formula (I) according to the invention has been found, characterized in that
compounds of the general formula (II)
R'
I . NH (II)
FT
in which
R and R~ have the abovementioned meaning
are reacted with compounds of the general formula (III)
T-CO,-A (III)
which
A has the abovementioned meaning
and
T represents halogen, preferably chlorine,
in solvents, if appropriate in the presence of a base and or in the presence of an auxiliary
The process according to the invention can be illustrated by way of example by the following equation
Suitable solvents are generally customary organic solvents which do not change under the reaction conditions T hese include ethers such as diethyl ether, dioxane or tetrahydrofuran, acetone, dimethylsulfoxide, dimethylformamide or alcohols such as methanol, ethanol, propanol or halogenohydrocarbons such as dichlor- methane, tπchloromethane or tetrachloromethane Tetrahydrofuran is preferred
Suitable bases are generally inorganic or organic bases These preferably include alkali metal hydroxides such as, for example, sodium hydroxide, sodium hydrogen- carbonate or potassium hydroxide, alkaline earth metal hydroxides such as, for example, barium hydroxide, alkali metal carbonates such as sodium carbonate, potassium carbonate, alkaline earth metal carbonates such as calcium carbonate, or alkaline metal or organic amines (trialkyl(C]-C6)amines) such as triethylamine, or heterocycles such as l,4-dιazabιcyclo[2 2 2]octane (DABCO), 1,8-dιazabιcyclo- [5 4 0]undec-7-ene (DBU), or amides such as sodium amides, lithium butyl amide or butyllithium, pyridine or methylpipeπdine It is also possible to employ alkali metals, such as sodium or its hydrides such as sodium hydride, as bases
Potassium carbonate, triethylamine, sodium hydrogencarbonate and sodium- hydroxide are preferred
The process is in general carried out in a temperature range from 0°C to +100°C, preferably from room temperature to +60°C
The process is generally carried out at normal pressure However, it is also possible to carry out it at elevated pressure or at reduced pressure (for example in a range from 0 5 to 5 bar)
The base is employed in an amount from 1 mol to 10 mol, preferably from 1 0 mol to 4 mol, relative to 1 mol of the compounds of the general formula (III)
The compounds of the general formula (II) are known or can be prepared by customary methods
The compounds of the general formula (III) are known or can be prepared by customary methods
The carbamic acid derivatives of the general formula (I) can be employed as active compounds in medicaments. The substances can act as inhibitors of enzy¬ matic reactions in the context of arachidonic acid metabolism.
The compounds of the general formula (I) surprisingly show a high activity as inhibitors of leukotriene synthesis, specifically inhabit the production of leuko¬ triene B4 in polymorphonuclear leucocytes (PMNL).
They are therefore preferably suitable for the treatment and prevention of diseases of the respiratory passages, such as allergies/asthma, bronchitis, emphysema, shock lung, pulmonary hypertension, inflammations/rheumatism and oedemas, thrombo- ses and thromboembolism, ischaemis (disturbances in peripheral, cardiac and cere¬ bral circulation), cardiac and cerebral infarctions, disturbances in cardiac rhythm, angina pectoris and arteriosclerosis, in the event of tissue, transplants, dermatoses, such as psoriasis, inflammatory dermatoses, for example eczema, dermatophyte infection, infections of the skin by bacteria, metastases and for cytoprotection in the gastrointestinal tract.
lest description
1 Preparation of human PMNL
Blood was taken from healthy subjects by venous puncture and neutrophils were purified by dextran sedimentation and resuspended in the buffered medium
2 Inhibition of thaspsigargin-induced leuktoπene B4 generation Neutrophils (4 x 105 cells/ml) were placed in a 96 well microtitre plate and prewarmed to 37°C Compounds according to the invention were added in dimethyl sulphoxide (DMSO) Compound concentration ranged from 0 3 to 30 μfvl, the DMSO concentration was < 0 3% v/v The plate was incubated for 5 min at 37°C Neutrophils were then stimulated by addition of 1 μM thapsigargin followed by 1 3 M Ca' 1 The reaction was stopped after 5 minutes and supernatants assayed for the presence of leukotriene (LT) B4 using an LTB4-specιfic radioimmunoassay kit supplied by Amersham Internationl pic Percentage inhibition was determined by comparison with vehicle-containing controls
The new active compounds can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, nontoxic, pharmaceuti- cally suitable excipients or solvents In this connection, the therapeutically active compound should in each case be present in a concentration of about 0 5 to 90% by weight of the total mixture, l e in amounts which are sufficient in order to achieve the dosage range indicated
The formulations are prepared, for example, by extending the active compounds with solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, where, for example, in the case of the use of water as a diluent, organic solvents can be used as auxiliary solvents if appropriate
Administration is carried out in a customary manner, preferably orally or paren¬ terally, in particular perhngually or intravenously
In the case of parenteral administration, solutions of the active compound can be employed using suitable liquid vehicles
In general, it has proved advantageous on intravenous administration to administer amounts from about 10 to 100 mg/kg, preferably about 10 to 50 mg/kg of body weight to achieve effective results, and on oral administration the dosage is about 10 to 100 mg/kg, preferably 10 to 50 mg/kg of body weight
In spite of this, it may be necessary to depart from the amounts mentioned, in par¬ ticular depending on the body weight or the type of application route, on indivi¬ dual behaviour towards the medicament, the manner of its formulation and the time or interval at which administration takes place Thus, in some cases it may be sufficient to manage with less than the abovementioned minimum amount, while in other cases the upper limit mentioned must be exceeded In the case of admini¬ stration of relatively large amounts, it is advisable to divide these into several individual doses over the course of the day
Preparation example
Example 1
Menthyloxycarbonyl-2-anιlιnopyridine
To a suspension of 500 mg (2 9 mmol) 2-anilino-pyπdine in saturated aqueous
NaHCO were added 0 94 ml (1 5 eq) (-)-menthyl chloroformate in 1 ml THF After 45 min the aqueous phase was extracted with ethyl acetate, the organic phase dried over MgSO4 and concentrated under reduced pressure The crude product was recrystalized from ether / PE, yielding 287 mg (27 6%) The mother liquor was carefully concentrated and the precipitate filtered off, yielding another
286 mg (27 5%)
Η-NMR (300 MHz, CDC13) δ = 0 77 (d, 3H), 0 81 (d, 3H), 0 89 (d, 3H), 0 72 - 1.22 (m, 4H), 1.41 - 1 54 (m, IH), 1.57 - 1 65 (m, 2H), 1 76 - 1 86 (dddd, IH), 2 12 -2 19 (m, IH), 4 62 - 4 71 (dt, IH), 7 04 - 7 08 (dddd, IH), 7 19 - 7 27 (m, 3H), 7 33 - 7 38 (m, 2H), 7 57 (d, IH), 7 69 (dt, IH), 8 36 (m, IH)
MS (70 eV) e/m [%] = 352 [M ]
The compounds shown in table 1 are prepared in analogy to the procedure of example 1
Table 1:
Claims
1. Carbamic acid derivatives of the general formula (1)
R '
2 / . (I)
R C02-A
in which
R represents a 6 membered aromatic heterocycle having up to 2 nitrogen atoms and to which a phenyl ring can be fused and wherein the rings optionally are monosubstituted or disubstituted by identical or different substituents from the series comprising halo¬ gen, carboxyl, nitro, a straight-chain or branched alkoxycarbonyl having up to 6 carbon atoms or by a group or the formula
-(CO) -NR3R4,
in which
a denotes a number 0 or 1 ,
R3 and R4 are identical or different and denote hydrogen, biphenyl, phenyl, adamantyl or straight-chain or branched alkyl or acyl each having up to 6 carbon atoms, which optionally are monosubstituted or disubstituted by phenyl and/or hydroxyl,
R" represents adamantyl, cycloalkyl having 3 to 6 carbon atoms, pyridyl, phenyl or benzyl, which optionally are substituted by halogen, carboxyl or straight-chain or branched alkoxy or alkoxycarbonyl each having up to 6 carbon atoms, or
or
R and R~ including the nitrogen atom together form a residue of a formula
represents adamantyl, dicyclohexylmethyl, cyclododecanyl, cis-deca- hydro-1 -naphthyl, 4-tert butylphenyl, 2-naphthyl, 2,6-diphenyl- phenyl, dibenzosuberolyl, 2-methylbenzyl, α-cyclopropyl -benzyl, 9- hydroxy-phenanthrenyl, 4-tπtylphenyl or
represents a residue of the formula
and their salts
Carbamic acid derivatives of the formula according to Claim 1,
wherein
R represents isoquinolyl, pyrazinyl, pyridyl or pyrimidyl, which optionally are monosubstituted or disubstituted by identical or different substituents from the series comprising fluorine, chlorine, bromine, iodine, carboxyl, nitro, a straight-chain or branched alk- oxycarbonyl having up to 5 carbon atoms or by a group of the formula -(CO) ,-NR3R4,
in which
a denotes a number 0 or 1,
R3 and R4 are identical or different and denote hydrogen, biphenyl, phenyl, adamantyl or straight-chain or branched alkyl or acyl each having up to 5 carbon atoms, which optionally are monosubstituted or disubstituted by phenyl and/or hydroxyl,
R2 represents cyclopentyl, cyclohexyl, pyridyl, phenyl or benzyl, which optionally are substituted by fluorine, chlorine, bromine, carboxyl or straight-chain or branched alkoxy or alkoxycarbonyl each having up to 4 carbon atoms, or represents a group of the formula
or
R and R~ including the nitrogen atom together form a residue of a formula
represents adamantyl, dicyclohexylmethyl, cvclododecanyl, cis-deca- hydro- 1-naphthyl, 4-tert butylphenyl, 2-naphthyl, 2,6-dιphenyl- phenyl, dibenzosuberolyl, 2-methyl benzyl, -cyclopropyl-benzyl, 9- hydroxy-phenanthrenyl, 4-tπtylphenyl, or a residue of the formula
Carbamic acid derivatives of the formula according to Claim 1,
wherein
R! represents pyridyl or pyrimidyl, which optionally are monosub¬ stituted or disubstituted by identical or different substituents from the series comprising fluorine, chlorine, bromine, carboxyl, nitro, a straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms or by a group of the formula -(CO) L-NR R4,
in which
denotes a number 0 or 1,
W and R are identical or different and denote hydrogen, biphenyl, phenyl or adamantyl, straight-chain or branched alkyl or acyl each having up to 3 carbon atoms, which optionally are monosubstituted or disubstituted by phenyl and/or hydroxyl,
R2 represents cyclopentyl, cyclohexyl, pyridyl or phenyl, which are optionally substituted by fluorine, chlorine, bromine, carboxvl or
straight-chain or branched alkoxy oi alkoxycarbonyl each having up to 3 carbon atoms, or represents a group of the formula
represents adamantyl, dicyclohexylmethyl, cyclododecanyl, cis- decahydro-1 -naphthyl, 4-tert butylphenyl, 2-naphthyl, 2,6-dιphenyl- phenyl, dibenzosuberolyl, 2-methylbenzyl, α-cyclopropyl-benzyl, 9- hydroxy-phenanthrenyl, 4-trityl phenyl, or a residue of the formula
and their salts
Carbamic acid derivatives according to Claim 1 to 3, for therapeutic use
Process for the preparation of carbamic acid derivatives according to Claims 1 to 3, characterized in that
compounds of the general formula (II)
R'
I (II)
. NH
R^
in which
R1 and R have the abovementioned meaning
are reacted with compounds of the general formula (III)
T-CO -A (III)
in which
A has the abovementioned meaning
and
T represents halogen, preferably chlorine,
in solvents, if appropriate in the presence of a base and/or in the presence of an auxiliary
Medicaments consisting of at least one carbamic acid derivative according to Claims 1 to 3 and a pharmacologically acceptable diluent
A medicament according to Claim 6 as inhibitor of the leukotrienes synthesis
Process for the preparation of a medicament according to Claims 6 and 7, characterized in that the carbamic acid derivative is brought into a suitable administration form if appropriate with the aid of customary auxiliaries and excipients
Use of the carbamic acid derivatives according to Claim 1 to 3 for the production of medicaments
Use according to Claim 1 for the production of inhibitors of the leuko- tπenes synthesis
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU10941/97A AU1094197A (en) | 1995-12-11 | 1996-11-28 | Carbamic acid derivatives as leukotriene antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9525261.5 | 1995-12-11 | ||
GBGB9525261.5A GB9525261D0 (en) | 1995-12-11 | 1995-12-11 | Carbamic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997021678A1 true WO1997021678A1 (en) | 1997-06-19 |
Family
ID=10785230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/005248 WO1997021678A1 (en) | 1995-12-11 | 1996-11-28 | Carbamic acid derivatives as leukotriene antagonists |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU1094197A (en) |
GB (1) | GB9525261D0 (en) |
WO (1) | WO1997021678A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6780861B2 (en) | 2000-05-05 | 2004-08-24 | Novartis Ag | Azabicyclic carbamates and their use as α-7 nicotinic acetylcholine receptor agonists |
WO2006019874A1 (en) * | 2004-07-14 | 2006-02-23 | Inflammation Research Center Company Ltd. | Method for inhibiting tumor metastasis |
WO2010097480A3 (en) * | 2010-05-25 | 2011-04-14 | Symrise Ag | Menthyl carbamate compounds as skin and/or hair lightening actives |
WO2010097479A3 (en) * | 2010-05-25 | 2011-04-14 | Symrise Ag | Cyclohexyl carbamate compounds as active anti-cellulite ingredients |
WO2010089421A3 (en) * | 2010-05-25 | 2011-04-14 | Symrise Ag | Menthyl carbamate compounds as active anti-cellulite ingredients |
WO2010122178A3 (en) * | 2010-05-25 | 2011-04-14 | Symrise Ag | Cyclohexyl carbamate compounds as skin and/or hair lightening actives |
EP2389922A1 (en) * | 2010-05-25 | 2011-11-30 | Symrise AG | Cyclohexyl carbamate compounds as anti-ageing actives |
KR20200128028A (en) * | 2018-02-26 | 2020-11-11 | 닛뽄 가야쿠 가부시키가이샤 | Base-reactive resin composition containing base proliferating agent and said base proliferating agent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0518818A2 (en) * | 1991-06-11 | 1992-12-16 | Ciba-Geigy Ag | Arylethers, their manufacture and use as medicament |
-
1995
- 1995-12-11 GB GBGB9525261.5A patent/GB9525261D0/en active Pending
-
1996
- 1996-11-28 WO PCT/EP1996/005248 patent/WO1997021678A1/en active Application Filing
- 1996-11-28 AU AU10941/97A patent/AU1094197A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0518818A2 (en) * | 1991-06-11 | 1992-12-16 | Ciba-Geigy Ag | Arylethers, their manufacture and use as medicament |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6780861B2 (en) | 2000-05-05 | 2004-08-24 | Novartis Ag | Azabicyclic carbamates and their use as α-7 nicotinic acetylcholine receptor agonists |
KR101213926B1 (en) | 2004-07-14 | 2012-12-18 | 인플러메이션 리서치 센터 컴퍼니 엘티디. | Method and pharmaceutical composition for inhibiting tumor metastasis |
WO2006019874A1 (en) * | 2004-07-14 | 2006-02-23 | Inflammation Research Center Company Ltd. | Method for inhibiting tumor metastasis |
EP1997491A1 (en) * | 2004-07-14 | 2008-12-03 | Inflammation Research Center Company Ltd. | Method for inhibiting tumor metastasis |
CN103025311A (en) * | 2010-05-25 | 2013-04-03 | 西姆莱斯有限公司 | Menthyl carbamate compounds as skin and/or hair lightening actives |
JP2013533218A (en) * | 2010-05-25 | 2013-08-22 | シムライズ アーゲー | Cyclohexyl carbamate compounds as anti-cellulite active ingredients |
WO2010122178A3 (en) * | 2010-05-25 | 2011-04-14 | Symrise Ag | Cyclohexyl carbamate compounds as skin and/or hair lightening actives |
EP2389922A1 (en) * | 2010-05-25 | 2011-11-30 | Symrise AG | Cyclohexyl carbamate compounds as anti-ageing actives |
WO2010097479A3 (en) * | 2010-05-25 | 2011-04-14 | Symrise Ag | Cyclohexyl carbamate compounds as active anti-cellulite ingredients |
CN103002868A (en) * | 2010-05-25 | 2013-03-27 | 西姆莱斯有限公司 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients |
WO2010097480A3 (en) * | 2010-05-25 | 2011-04-14 | Symrise Ag | Menthyl carbamate compounds as skin and/or hair lightening actives |
JP2013526592A (en) * | 2010-05-25 | 2013-06-24 | シムライズ アーゲー | Cyclohexyl carbamate compounds as lightening actives for skin and / or hair |
JP2013531629A (en) * | 2010-05-25 | 2013-08-08 | シムライズ アーゲー | Menthyl carbamate compounds as skin and / or hair lightening actives |
WO2010089421A3 (en) * | 2010-05-25 | 2011-04-14 | Symrise Ag | Menthyl carbamate compounds as active anti-cellulite ingredients |
US9012497B2 (en) | 2010-05-25 | 2015-04-21 | Symrise Ag | Cyclohexyl carbamate compounds as active anti-cellulite ingredients |
US9060949B2 (en) | 2010-05-25 | 2015-06-23 | Symrise Ag | Menthyl carbamate compounds as skin and/or hair lightening actives |
US9072676B2 (en) | 2010-05-25 | 2015-07-07 | Symrise Ag | Cyclohexyl carbamate compounds as skin and/or hair lightening actives |
CN103025311B (en) * | 2010-05-25 | 2016-03-16 | 西姆莱斯有限公司 | As the carbamic acid menthyl ester compound of skin and/or hair whitening active thing |
KR20200128028A (en) * | 2018-02-26 | 2020-11-11 | 닛뽄 가야쿠 가부시키가이샤 | Base-reactive resin composition containing base proliferating agent and said base proliferating agent |
US11401370B2 (en) * | 2018-02-26 | 2022-08-02 | Nippon Kayaku Kabushiki Kaisha | Base proliferating agent, and base-reactive resin composition containing said base proliferating agent |
TWI781295B (en) * | 2018-02-26 | 2022-10-21 | 日商日本化藥股份有限公司 | Base proliferating agent and base reactive resin composition containing the base proliferating agent |
US11905361B2 (en) | 2018-02-26 | 2024-02-20 | Nippon Kayaku Kabushiki Kaisha | Base proliferating agent, and base-reactive resin composition containing said base proliferating agent |
Also Published As
Publication number | Publication date |
---|---|
GB9525261D0 (en) | 1996-02-07 |
AU1094197A (en) | 1997-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997024328A1 (en) | 2-amino-heterocycles and therapeutic uses therefor | |
CA2559036C (en) | 9-substituted 8-oxoadenine compound | |
KR20180043329A (en) | [4- (1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl) phenoxy] ethyloxy compound or its salt | |
US6479488B1 (en) | Tetrahydroquinoline derivatives as EAA antagonists | |
KR900012919A (en) | Benzo fused N-containing heterocycle derivatives | |
JPWO2015129809A1 (en) | Pharmaceutical composition for the treatment of ischemic eye disease | |
EP2064177A2 (en) | Protease inhibitors | |
EA000308B1 (en) | Indole derivatives as eaa antagonists | |
US6300337B1 (en) | Acetamide derivative and use thereof | |
WO1997021678A1 (en) | Carbamic acid derivatives as leukotriene antagonists | |
US5179106A (en) | Substituted n-(quinolin-2-yl-methoxy) benzyl-sulphonylurea leukotriene synthesis inhibitors | |
HUT65384A (en) | Process for preparation of novel benzopyrane derivatives and pharmaceutical compositions containing them | |
EP0551662A1 (en) | Benzofuranyl- and thiophenylmethylthio-alcanecarboxylic acid derivatives | |
JP2010024243A (en) | Benzo[g]quinoline derivative for treatment of glaucoma and myopia | |
EP0419676B1 (en) | Thionaphthalene derivatives, method of producing the same, and antiallergic agent containing the same | |
AU660742B2 (en) | Thiazolyl-substituted quinolylmethoxphenylacetic acid derivatives | |
JP3426242B2 (en) | Diazacycloalkane alkylsulfonamide derivatives | |
JP2567593B2 (en) | Imidazolidinetrione derivative and therapeutic agent for allergic disease containing the compound as an active ingredient | |
WO1997022588A1 (en) | Use of hetarylacetic acid derivatives as leukotriene inhibitors | |
EP0654026B1 (en) | Isoserine derivatives and their use as leukotriene antagonists | |
US20100063035A1 (en) | Carbonic anhydrase inhibitors derivatives | |
AU2002328856A1 (en) | Benzo (G) quinoline derivatives for treating glaucoma and myopia | |
JPH02273661A (en) | Substituted (quinoline-2-yl-methoxy)phenyl- n,n'-sulfonylureas, their preparation method and use for remedy | |
US5356922A (en) | Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates | |
NO313413B1 (en) | Hydroquinone derivative, its use and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR BY CA CN CZ EE HU IL IS JP KE KP KR LT LV MX NO NZ PL RO RU SG SI SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97521660 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |